Ataxia telangiectasia in Turkey:multisystem involvement of 91 patients
Ataxia telangiectasia in Turkey:multisystem involvement of 91 patients作者机构:Department of Pediatric Infectious Diseases and Clinical Immunologylstanbul Medical Facultylstanbul University Department of Pediatric Neurologylstanbul Medical Facultylstanbul University Department of Medical Geneticslstanbul Medical Facultylstanbul University
出 版 物:《World Journal of Pediatrics》 (世界儿科杂志(英文版))
年 卷 期:2017年第13卷第5期
页 面:465-471页
核心收录:
学科分类:1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题:ataxia telangiectasia immunodeficiency malignancies neurological impairment
摘 要:Background:Ataxia telangiectasia (AT) is a genetically based multisystemic *** aimed to make a comprehensive evaluation of multisystem involvement in AT by describing clinical features and outcome of 91 ***:Medical records of the patients who were diagnosed and followed by a multidisciplinary approach during a 27-year period (1988-2015) were reviewed ***:Forty six female and 45 male patients with a mean follow-up period of 39.13±4.28 months were *** mean age at the time of symptom onset and diagnosis were 15.4±1.09 months and 73.6144.11 months,*** abnormalities were progressive truncal ataxia,nystagmus,dysarthria,oculomotor apraxia and *** one patients (34.1%) became dependent on wheelchair at a mean age of 12.1±2.8 *** patients (12.1%) became bedridden by a mean age of 14.7±1.8 *** magnetic resonance imaging revealed pathological findings in 47/66 *** immunological parameters were determined in 51/91 patients:immunoglobulin (Ig)A deficiency (n=38),lymphopenia (n=30),IgG (n=15) and IgG2 (n=11) *** of recurrent sinopulmonary infections (n=45) and bronchiectasis (n=22) were found to be more common in patients with impaired immunological parameters (P=0.029and P=0.023,respectively).Malignancy developed in 5 patients,being mostly lymphoreticular in origin and resulted in death of 4 ***:AT is a long lasting disease with muitisystem involvement necessitating multidisciplinary follow up,as described in our *** diagnosis of malignancy and supportive treatments regarding pulmonary and neurological health may prolong survival and increase the quality of life.